Posted by Michael Wonder on 29 Sep 2021
NuCana receives fast track designation from the U.S. Food and Drug Administration for Acelarin (NUC-1031) for the treatment of biliary tract cancer
29 September 2021 - NuCana announced that the U.S. FDA has granted fast track designation to Acelarin (NUC-1031), currently being evaluated in a Phase 3 trial (NuTide:121) for the first-line treatment of patients with advanced biliary tract cancer.
Acelarin (NUC-1031) and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents.
